The Health Tech Investment Act proposes expanded Medicare reimbursement for FDA-approved AI medical devices, supported by Nexalin Technology to improve access and innovation in healthcare.
April 2025 update on U.S. pharmaceutical regulation highlights executive orders, budget changes, CMS policies, IRA litigation, and 340B program developments shaping drug pricing and access.
The Health Tech Investment Act aims to create a consistent Medicare payment system for FDA-approved AI medical devices, enhancing patient access and improving healthcare outcomes.
Dr. Mehmet Oz confirmed as CMS leader, emphasizing Medicare and Medicaid modernization, targeting fraud, and navigating potential Medicaid funding challenges amid federal budget pressures.
Holly Hill mental health hospital in North Carolina addresses CMS and NCDHHS compliance issues to maintain Medicare program eligibility. Follow-up inspection results pending.
Maine advocates seek Medicare coverage for anti-obesity medications to improve public health, reduce healthcare costs, and promote active transportation. Bipartisan support grows with Senator Susan Collins' leadership.
Analysis of the Trump administration's increased use of executive power, constitutional implications, impact on economic policy, and market stability risks.
Medicare Advantage enrollment growth slows in 2025 with for-profit plans covering three-quarters of beneficiaries. Quality ratings decline and workforce shortages drive interest in advanced practice providers and AI solutions.
CMS finalizes key elements of the CY 2026 Medicare Advantage and Medicare Part D final rule, including insulin coverage expansion, Prescription Payment Plan codification, pharmacy data requirements, and updated enrollee protections.
CMS increases 2026 Medicare Advantage reimbursement rates to 5.06%, easing insurer pressures while adjusting policies on obesity drug coverage and billing practices.
